Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIFU + cindilizumab + bevacizumab for advanced hepatocellular carcinoma
ChiCTR2100046243Phase 2Recruiting
- Sponsor
- The 2nd Affiliated Hospital of Chongqing Medical University
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and bevacizumab in hepatocellular carcinoma (HCC), sponsored by The 2nd Affiliated Hospital of Chongqing Medical University. Primary endpoint: Immunotherapy efficacy by immune-related response criteria. Started Jun 2021; status: recruiting.
02
Drugs
sintilimabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100046243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046243.